Enzalieva 40mg Capsule: Advanced Androgen Receptor Inhibition for Global Prostate Cancer Care Are you searching for a verified Enzalieva 40mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical androgen receptor inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Enzalieva 40mg? Enzalieva 40mg is an oral targeted therapy containing the active pharmaceutical ingredient Enzalutamide. Manufactured by Allieva, this 40mg capsule is a potent, non-steroidal androgen receptor inhibitor. It is a cornerstone treatment in modern uro-oncology, specifically designed to combat prostate cancer by blocking the hormones that fuel tumor growth, even when traditional hormone therapies have failed. 1. Therapeutic Indications Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread and no longer responds to surgical or medical treatments that lower testosterone. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): For patients whose cancer has not spread but is at high risk of progressing despite androgen deprivation therapy. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with androgen deprivation therapy for patients with metastatic disease that still responds to hormone suppression. 2. Mechanism of Action: The Triple-Blockade Strategy Binding Inhibition: It competitively inhibits the binding of androgens (like testosterone) to the androgen receptors within the prostate cancer cells. Nuclear Translocation Inhibition: It prevents the androgen receptor from moving into the cell nucleus, a critical step required for cancer cell signaling. DNA Binding Inhibition: Even if the receptor reaches the nucleus, Enzalieva prevents it from binding with DNA, effectively “turning off“ the genetic instructions that tell the cancer cell to grow and divide. 3. Administration and Dosing Standard Dosage: The typical dose is 160mg (four 40mg capsules) taken once daily. Consistency: It can be taken with or without food. Maintaining a daily routine at the same time is essential for therapeutic efficacy. Handling: Capsules must be swallowed whole and should not be chewed, dissolved, or opened. Clinical Side Effects & Safety Monitoring Fatigue: Significant tiredness or lack of energy is the most commonly reported side effect. Gastrointestinal: Decreased appetite, constipation, or diarrhea. Musculoskeletal: Back pain, joint pain (arthralgia), and an increased risk of falls or fractures. Neurological Risks: While rare, there is a potential risk of seizures; patients with a history of brain injury or seizures should be monitored closely. Cardiovascular: Potential for high blood pressure (hypertension) and ischemic heart disease. General: Hot flushes and peripheral edema (swelling of the extremities). Why Source Enzalieva 40mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Enzalieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, urology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp